Meta-Analysis of Capecitabine versus 5-Fluorouracil in Advanced Gastric Cancer

Table 2

Safety analysis of capecitabine and 5-fluorouracil.

Adverse reactions	Capecitabine arm (number of events/sample size)	5-Fluorouracil group (# events/sample size)	RR	95% CI	Value	I^2 (%)
Thrombocytopenia	130/811	146/813	0.79	0.38–1.62	0.52	82
Nausea and vomiting	580/969	598/969	0.97	0.91–1.03	0.27	0
Hand-foot syndrome	300/878	173/872	2.00	1.21–3.31	0.007	69
Alopecia	454/689	477/693	0.95	0.89–1.02	0.17	26
Stomatitis	238/878	322/872	0.73	0.64–0.84	<0.0001	40
Diarrhea	372/878	364/872	1.02	0.78–1.33	0.90	67